Skip to content
10-Q

Quarterly Report

BIOLARGO, INC. BLGO

0001437749-26-017391

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 320.88M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.92M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.83M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $4.12M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.88M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.79M
Stockholders Equity Q1 2026 · Dec 31, 2025 $4.04M
Current Liabilities Q1 2026 · Mar 31, 2026 $4.93M
Current Liabilities Q1 2026 · Dec 31, 2025 $5.06M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.75M
Total Liabilities Q1 2026 · Dec 31, 2025 $6.79M
Current Assets Q1 2026 · Mar 31, 2026 $5.45M
Current Assets Q1 2026 · Dec 31, 2025 $5.11M
Total Assets Q1 2026 · Mar 31, 2026 $8.57M
Total Assets Q1 2026 · Dec 31, 2025 $8.31M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.01
Eps Basic restated Q1 2026 · Mar 31, 2025 $0.00
Sga Expense Q1 2026 · Mar 31, 2026 $2.76M
Sga Expense restated Q1 2026 · Mar 31, 2025 $2.52M
Rd Expense Q1 2026 · Mar 31, 2026 $907K
Rd Expense Q1 2026 · Mar 31, 2025 $791K
Operating Income Q1 2026 · Mar 31, 2026 −$3.2M
Operating Income Q1 2026 · Mar 31, 2025 −$1.86M
Gross Profit Q1 2026 · Mar 31, 2026 $458K
Gross Profit Q1 2026 · Mar 31, 2025 $1.49M